ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of medical
devices and related software solutions, announced today that the Medical
Device Network has named the LifeVest® Wearable Defibrillator
as one of the five most innovative and life-changing medical devices of
2009.
“The LifeVest Wearable Defibrillator has
protected more than 21,000 patients at high risk of sudden cardiac
arrest.”
Reporter Frances Penwill-Cook of the U.K.-based Medical Device Network
explained, “The LifeVest was selected because we felt it was
technologically exceptional, that it would experience widespread use due
to excellent functionality and that it would have a significant impact
on patient care.”
“To receive this designation from a large and respected internet
reference portal indicates that the LifeVest is gaining visibility on
the international front as a standard of care,” said Richard A. Packer,
Chairman and CEO of ZOLL. “The LifeVest Wearable Defibrillator has
protected more than 21,000 patients at high risk of sudden cardiac
arrest.”
The LifeVest Wearable Defibrillator is worn by patients at risk for
sudden cardiac arrest (SCA), providing protection during their changing
condition and while permanent SCA risk has not been established. The
LifeVest allows a patient’s physician time to assess his or her
long-term arrhythmic risk and make appropriate plans.
The LifeVest is lightweight and easy to wear, allowing patients to
return to their activities of daily living, while having the peace of
mind that they are protected from SCA. The LifeVest continuously
monitors the patient’s heart and, if a life-threatening heart rhythm is
detected, the device delivers a treatment shock to restore normal heart
rhythm.
The LifeVest is used for a wide range of patient conditions or
situations, including following a heart attack, before or after bypass
surgery or stent placement, as well as for those with cardiomyopathy or
congestive heart failure that places them at particular risk.
Decoding the genetic roots of stroke and heart attack